NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report

•<1% of cervical cancers are sarcomas.•Data on neurofibrosarcoma management is scarce.•Larotrectinib is approved for NTRK1 gene fusion tumors without acquired resistance.•Targeted therapy of tumor genes may expand treatment for a rare cervical sarcoma.

Saved in:

Bibliographic Details
Published in:	Gynecologic oncology reports Vol. 28; pp. 141 - 144
Main Authors:	Wells, A.E., Mallen, A.M., Bui, M.M., Reed, D.R., Apte, S.M.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Inc 01-05-2019 Elsevier
Subjects:	Case Report Cervical cancer Larotrectinib Malignant peripheral nerve sheath tumor Neurofibrosarcoma NTRK-1 Targeted therapy Larotrectinib NTRK-1 Neurofibrosarcoma Targeted therapy Cervical cancer Malignant peripheral nerve sheath tumor
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•<1% of cervical cancers are sarcomas.•Data on neurofibrosarcoma management is scarce.•Larotrectinib is approved for NTRK1 gene fusion tumors without acquired resistance.•Targeted therapy of tumor genes may expand treatment for a rare cervical sarcoma.
ISSN:	2352-5789 2352-5789
DOI:	10.1016/j.gore.2019.04.006